openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Warnings sections page 1 of 1 · 1 matching rows.
warnings
WARNINGS Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people. Do NOT add dopamine HCl to any alkaline diluent solution since the drug is inactivated in alkaline solution. Patients who have been receiving MAO inhibitors prior to the administration of dopamine HCl will require substantially reduced dosage. See Drug Interactions below.
ADVERSE REACTIONS The following adverse reactions have been observed, but there are not enough data to support an estimate of their frequency. Cardiovascular System: -ventricular arrhythmia -atrial fibrillation -ectopic beats -tachycardia -anginal pain -palpitation -cardiac conduction abnormalities -widened QRS complex -bradycardia -hypotension -hypertension -vasoconstriction Respiratory System: -dyspnea Gastrointestinal System: -nausea -vomiting Metabolic/Nutritional System: -azotemia Central Nervous System: -headache -anxiety Dermatological System: -piloerection Other: Gangrene of the extremities has occurred when high doses were administered for prolonged periods or in patients with occlusive vascular disease receiving low doses of dopamine HCl. To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1‐877‐233‐2001 or FDA at 1‐800‐FDA‐1088 or www.fda.gov/medwatch.